Sign in
Taking people in United StatesNo phase

Collects tissue and samples from people with mesothelioma and mesothelin-linked cancers

Studies patients with mesothelioma and other mesothelin-expressing cancers, collecting samples and follow-up data.

Key facts

Who runs it
National Cancer Institute (NCI)
Where
Bethesda, United StatesSee the site
Trial code
Registry title
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Status
Recruiting
People taking part
1,000 people, planned
Started
9 Sept 2013
Expected to end
25 Jul 2033
Type of study
Observational
Record updated
12 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with malignant mesothelioma or other cancers that make mesothelin, a protein on tumor cells. They give blood, urine, tumor and fluid samples and are followed over time.

Age
2 Years to 100 Years. People with mesothelioma can join from age 2. People with the other cancers must be 18 or older.
Sex
All sexes can join.
Disease stage
Malignant mesothelioma, or thymic carcinoma, pancreatic or biliary adenocarcinoma, or lung, gastric or ovarian cancer, or another solid tumor known to express mesothelin. The diagnosis must be confirmed by tissue testing.
Biomarker or test result
For cancers other than mesothelioma, the solid tumor must be known to express mesothelin.

Main reasons for not taking part

  • Active serious organ disease that makes a biopsy riskier, such as heart disease, recent heart attack, heart failure or lung problems
  • Pregnant women
  • Other active medical or mental illness that may raise the risk, as judged by the lead doctor
  • Adults unable to give informed consent

The registry criteria, word for word

Show all 8 criteriaShow less

Who cannot take part

  • Active concomitant medical or psychological illnesses that may increase the risk to the participant or in adult participants, inability to obtain informed consent, at the discretion of the principal investigator
  • Active symptomatic major organ disorder that would increase the risk of biopsy, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, pulmonary dysfunction
  • Pregnant women

Other criteria

  • INCLUSION CRITERIA:
  • All participants >= 2 years of age with malignant mesothelioma
  • All participants >=18 years of age with thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers or other solid tumor known to express mesothelin
  • Confirmed pathological diagnosis is required
  • Ability and willingness of participant to provide informed consent to participation

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 2 and 100 years old?

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United StatesContact: Cathy I Wagner, R.N.Taking people

About the trial

What the trial wants to find out

Background:

Read full original descriptionShow less

* Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. * Mesothelioma accounts for 0.10% of deaths annually in the United States. Malignant pleural mesothelioma is the most common of these, comprising of 80% of the cases with an annual incidence of about 2,500 in the United States. * The median survival from diagnosis of pleural mesothelioma is approximately 12 months. The majority of patients present with stage III or IV disease with 85-90% of patients considered unresectable at diagnosis. * Peritoneal mesothelioma has a better prognosis than pleural mesothelioma; nevertheless, patients undergoing therapy for peritoneal mesothelioma have few well-studied treatment options due in large part to the rarity of the disease. * In addition to mesothelioma, mesothelin is highly expressed in several cancers, including pancreatic, biliary adenocarcinomas, gastric and ovarian cancers; mesothelin is also expressed in a significantly larger proportion of thymic carcinoma than thymoma.

Objectives:

-To allow sample acquisition for use in the study of mesothelioma.

Eligibility:

* All participants age greater than or equal to 2 years with malignant mesothelioma OR * All participants greater than or equal to 18 years with thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers or other solid tumor known to express mesothelin * Must be able and willing to provide informed consent if 18 or over; parent or guardian must be able and willing to provide consent for patients under the age of 18

Design:

* Up to 1000 subjects will be enrolled. * Patients will be followed to determine the course of disease and to record any treatment received for mesothelioma. * Patients will undergo sampling of blood, urine, tumor and abnormal body fluids for tissue banking. * Studies which may be performed on banked material include genetic and genomic studies, establishment of cell cultures and immunologic studies.

The group in the trial

  • 1/Eligible cancer diagnosis

    Subjects with mesothelioma, thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers or other solid tumor known to express mesothelin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma and Other Mesothelin Expressing Cancers
Plain-language title
Collects tissue and samples from people with mesothelioma and mesothelin-linked cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Fit questions
Built from NCT01950572, who can take part
Publications
Record updated
12 November 2026